CRVS (STOCKS)
Corvus Pharmaceuticals, Inc.
$15.140000
+0.090000 (+0.60%)
Prev close: $15.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard A. Miller
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,433.62M
- Employees
- 31
- P/E (TTM)
- -24.36
- P/B (TTM)
- 5.62
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.19 | $-0.16 | -0.0281 | -17.36% |
|
Mar 2026 (Q1)
|
$-0.15 | $-0.15 | -0.0043 | -2.95% |
|
Dec 2025 (Q4)
|
$-0.15 | $-0.13 | -0.0181 | -13.72% |
|
Sep 2025 (Q3)
|
$-0.12 | $-0.14 | +0.0161 | +11.83% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $56.96M |
| Depreciation and Amortization | $112.00K |
| Research and Development | $45.53M |
| Other Operating Expenses | $11.32M |
| Operating Income/Loss | -$56.96M |
| Income/Loss Before Equity Method Investments | -$51.79M |
| Income/Loss From Continuing Operations After Tax | -$52.39M |
| Income/Loss From Continuing Operations Before Tax | -$51.79M |
| Income/Loss From Equity Method Investments | -$2.34M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$54.13M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$54.13M |
| Net Income/Loss Available To Common Stockholders, Basic | -$54.13M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.61 |
| Diluted Earnings Per Share | -$0.61 |
| Basic Average Shares | 266,547,652 |
| Diluted Average Shares | 266,288,371 |
| Assets | $239.27M |
| Current Assets | $220.97M |
| Cash | $215.20M |
| Other Current Assets | $5.77M |
| Noncurrent Assets | $18.31M |
| Fixed Assets | $830.00K |
| Other Non-current Assets | $17.48M |
| Liabilities | $13.95M |
| Current Liabilities | $13.67M |
| Accounts Payable | $4.05M |
| Wages | $1.93M |
| Other Current Liabilities | $7.69M |
| Noncurrent Liabilities | $274.00K |
| Equity | $225.33M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $225.33M |
| Liabilities And Equity | $239.27M |
| Net Cash Flow From Operating Activities | -$44.53M |
| Net Cash Flow From Operating Activities, Continuing | -$44.53M |
| Net Cash Flow From Investing Activities | -$142.55M |
| Net Cash Flow From Investing Activities, Continuing | -$142.55M |
| Net Cash Flow From Financing Activities | $191.29M |
| Net Cash Flow From Financing Activities, Continuing | $191.29M |
| Net Cash Flow | $4.21M |
| Net Cash Flow, Continuing | $4.21M |
| Comprehensive Income/Loss | -$54.04M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$54.27M |
| Other Comprehensive Income/Loss | -$28.03M |